ArticleNature reviews. Clinical oncology2017
First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm.
Article in Nature reviews. Clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies.NPJ precision oncology · 2025Review
- Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.British journal of cancer · 2024Article
- Outcomes of upfront primary tumor resection in patients with synchronousAmerican journal of cancer research · 2024Article
- Loss ofEcancermedicalscience · 2024Article
- Review
- Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry.American journal of cancer research · 2023Article
- Review
- FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases.Annals of translational medicine · 2022Article
- Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.Cancers · 2022Review
- TRIM27 is an adverse prognostic biomarker and associated with immune and molecular profiles in right-sided colon cancer.American journal of cancer research · 2022Article
- Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases.Annals of surgical oncology · 2021Article
- Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway.Cell death & disease · 2021Article
- Right Versus Left Colon Cancer: Resectable and Metastatic Disease.Current treatment options in oncology · 2018Review
- A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer.International journal of molecular sciences · 2017Review
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28094264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.